Long COVID: General Perceptions and Challenges in Diagnosis and Management DOI Creative Commons

Katia Ozanic,

Aripuanã Sakurada Aranha Watanabe,

Andre Machado

и другие.

COVID, Год журнала: 2025, Номер 5(3), С. 41 - 41

Опубликована: Март 12, 2025

On 11 March 2020, the World Health Organization (WHO) declared a pandemic caused by SARS-CoV-2, raising global health concerns. Reports of persistent and new symptoms following acute phase infection highlighted complexities recovery prompted investigation what is now termed long COVID. Officially recognized WHO in October 2021, COVID presents various implications, though terminology—such as post-COVID syndrome post-acute sequelae COVID-19 (PASC)—remains inconsistent, complicating diagnostic standardization. Long affects an estimated 10% to 30% SARS-CoV-2-infected individuals, with common including fatigue, dyspnea, cognitive dysfunction, joint pain, all which significantly impair quality life. Public perception influenced factors like education history, while misinformation stigma hinder accurate diagnosis treatment. The absence biomarkers overlap other post-viral syndromes further complicate clinical recognition. Experts emphasize need for refined criteria integrated strategies combining biomedical research, public policy, educational initiatives improve management, address healthcare inequalities, mitigate impacts This review unveils state art knowledge gaps encourage discussion, aim achieving better decision-making awareness related

Язык: Английский

Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever DOI Open Access
Der‐Shan Sun,

Te-Sheng Lien,

Hsin‐Hou Chang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1898 - 1898

Опубликована: Фев. 22, 2025

Virus-induced antibodies represent a dual-edged sword in the immune response to viral infections. While are critical for neutralizing pathogens, some can paradoxically exacerbate disease severity through mechanisms such as antibody-dependent enhancement (ADE), autoantibody, and prolonged inflammation. Long coronavirus (COVID) dengue hemorrhagic fever (DHF) exemplify conditions where pathogenic play pivotal role progression. COVID is associated with persistent dysregulation autoantibody production, leading chronic symptoms tissue damage. In DHF, pre-existing against virus contribute ADE, amplifying replication, activation, vascular permeability. This review explores underlying these antibody responses, highlighting shared pathways of comparing distinct features both conditions. By examining studies, we identify key lessons therapeutic strategies, vaccine design, future research aimed at mitigating severe outcomes

Язык: Английский

Процитировано

0

Hyperthermia and targeting heat shock proteins: innovative approaches for neurodegenerative disorders and Long COVID DOI Creative Commons
David M. Smadja,

M. Marc Abreu

Frontiers in Neuroscience, Год журнала: 2025, Номер 19

Опубликована: Фев. 4, 2025

Neurodegenerative diseases (NDs) and Long COVID represent critical growing global health challenges, characterized by complex pathophysiological mechanisms including neuronal deterioration, protein misfolding, persistent neuroinflammation. The emergence of innovative therapeutic approaches, such as whole-body hyperthermia (WBH), offers promising potential to modulate underlying in NDs related conditions like COVID. WBH, particularly fever-range, enhances mitochondrial function, induces heat shock proteins (HSPs), modulates neuroinflammation—benefits that pharmacological treatments often struggle replicate. HSPs HSP70 HSP90 play pivotal roles folding, aggregation prevention, cellular protection, directly targeting pathological processes seen Alzheimer's, Parkinson's, Huntington's disease. Preliminary findings also suggest WBH's alleviate neurological symptoms COVID, where neuroinflammation serotonin dysregulation are prominent. Despite the absence robust clinical trials, implications WBH extend immune modulation restoration disrupted physiological pathways. However, dual nature hyperthermia's effects—balancing pro-inflammatory anti-inflammatory responses—emphasizes need for dose-controlled applications stringent patient monitoring minimize risks vulnerable populations. While shows interest, significant challenges remain. These include individual variability response, limited accessibility advanced technologies, standardized protocols. Future research must focus on targeted biomarker identification, personalized treatment strategies optimize efficacy integration into paradigms could mark a transformative step addressing these conditions.

Язык: Английский

Процитировано

0

A Machine-Learning Approach to Finding Gene Target Treatment Options for Long COVID DOI Creative Commons
Alejandro Lopez‐Rincon

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

Abstract Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), encompasses a range symptoms persisting for weeks or months after the acute phase COVID-19. These symptoms, affecting multiple organ systems, significantly impact quality life. This study employs machine-learning approach to identify gene targets treating COVID. Using datasets GSE275334, GSE270045, and GSE157103, Recursive Ensemble Feature Selection (REFS) was applied key genes associated with The highlights therapeutic potential targeting such PPP2CB, SOCS3, ARG1, IL6R, ECHS1. Clinical trials pharmacological interventions, including dual antiplatelet therapy anticoagulants, are explored their efficacy in managing COVID-19-related complications. findings suggest that machine learning can effectively biomarkers targets, offering promising avenue personalized treatment strategies COVID patients.

Язык: Английский

Процитировано

0

Long COVID: General Perceptions and Challenges in Diagnosis and Management DOI Creative Commons

Katia Ozanic,

Aripuanã Sakurada Aranha Watanabe,

Andre Machado

и другие.

COVID, Год журнала: 2025, Номер 5(3), С. 41 - 41

Опубликована: Март 12, 2025

On 11 March 2020, the World Health Organization (WHO) declared a pandemic caused by SARS-CoV-2, raising global health concerns. Reports of persistent and new symptoms following acute phase infection highlighted complexities recovery prompted investigation what is now termed long COVID. Officially recognized WHO in October 2021, COVID presents various implications, though terminology—such as post-COVID syndrome post-acute sequelae COVID-19 (PASC)—remains inconsistent, complicating diagnostic standardization. Long affects an estimated 10% to 30% SARS-CoV-2-infected individuals, with common including fatigue, dyspnea, cognitive dysfunction, joint pain, all which significantly impair quality life. Public perception influenced factors like education history, while misinformation stigma hinder accurate diagnosis treatment. The absence biomarkers overlap other post-viral syndromes further complicate clinical recognition. Experts emphasize need for refined criteria integrated strategies combining biomedical research, public policy, educational initiatives improve management, address healthcare inequalities, mitigate impacts This review unveils state art knowledge gaps encourage discussion, aim achieving better decision-making awareness related

Язык: Английский

Процитировано

0